429 related articles for article (PubMed ID: 33013832)
1. Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis.
Caputo S; Grioni M; Brambillasca CS; Monno A; Brevi A; Freschi M; Piras IS; Elia AR; Pieri V; Baccega T; Lombardo A; Galli R; Briganti A; Doglioni C; Jachetti E; Bellone M
Front Immunol; 2020; 11():1820. PubMed ID: 33013832
[TBL] [Abstract][Full Text] [Related]
2. Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation.
Jachetti E; Caputo S; Mazzoleni S; Brambillasca CS; Parigi SM; Grioni M; Piras IS; Restuccia U; Calcinotto A; Freschi M; Bachi A; Galli R; Bellone M
Cancer Res; 2015 May; 75(10):2095-108. PubMed ID: 25808872
[TBL] [Abstract][Full Text] [Related]
3. Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors.
Mazzoleni S; Jachetti E; Morosini S; Grioni M; Piras IS; Pala M; Bulfone A; Freschi M; Bellone M; Galli R
Stem Cells Transl Med; 2013 Sep; 2(9):678-89. PubMed ID: 23884639
[TBL] [Abstract][Full Text] [Related]
4. The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.
Su W; Han HH; Wang Y; Zhang B; Zhou B; Cheng Y; Rumandla A; Gurrapu S; Chakraborty G; Su J; Yang G; Liang X; Wang G; Rosen N; Scher HI; Ouerfelli O; Giancotti FG
Cancer Cell; 2019 Aug; 36(2):139-155.e10. PubMed ID: 31327655
[TBL] [Abstract][Full Text] [Related]
5. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
Peek EM; Song W; Zhang H; Huang J; Chin AI
Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
[TBL] [Abstract][Full Text] [Related]
6. Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer.
Ellerhorst J; Troncoso P; Xu XC; Lee J; Lotan R
Urol Res; 1999 Oct; 27(5):362-7. PubMed ID: 10550525
[TBL] [Abstract][Full Text] [Related]
7. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.
Laderach DJ; Gentilini LD; Giribaldi L; Delgado VC; Nugnes L; Croci DO; Al Nakouzi N; Sacca P; Casas G; Mazza O; Shipp MA; Vazquez E; Chauchereau A; Kutok JL; Rodig SJ; Elola MT; Compagno D; Rabinovich GA
Cancer Res; 2013 Jan; 73(1):86-96. PubMed ID: 23108139
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of C-CAM cell adhesion molecule in prostate carcinogenesis in a transgenic mouse model.
Pu YS; Luo W; Lu HH; Greenberg NM; Lin SH; Gingrich JR
J Urol; 1999 Sep; 162(3 Pt 1):892-6. PubMed ID: 10458403
[TBL] [Abstract][Full Text] [Related]
9. ETV4 promotes late development of prostatic intraepithelial neoplasia and cell proliferation through direct and p53-mediated downregulation of p21.
Cosi I; Pellecchia A; De Lorenzo E; Torre E; Sica M; Nesi G; Notaro R; De Angioletti M
J Hematol Oncol; 2020 Aug; 13(1):112. PubMed ID: 32791988
[TBL] [Abstract][Full Text] [Related]
10. Endogenous Galectin-1 in T Lymphocytes Regulates Anti-prostate Cancer Immunity.
Corapi E; Carrizo G; Compagno D; Laderach D
Front Immunol; 2018; 9():2190. PubMed ID: 30319642
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression.
Diener KR; Woods AE; Manavis J; Brown MP; Hayball JD
Lab Invest; 2009 Feb; 89(2):142-51. PubMed ID: 19079323
[TBL] [Abstract][Full Text] [Related]
12. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells.
De Marzo AM; Meeker AK; Epstein JI; Coffey DS
Am J Pathol; 1998 Sep; 153(3):911-9. PubMed ID: 9736039
[TBL] [Abstract][Full Text] [Related]
13. Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma.
Adisetiyo H; Liang M; Liao CP; Aycock-Williams A; Cohen MB; Xu S; Neamati N; Conway EM; Cheng CY; Nikitin AY; Roy-Burman P
PLoS One; 2013; 8(7):e69484. PubMed ID: 23936028
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
15. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes.
Miyazaki J; Hokari R; Kato S; Tsuzuki Y; Kawaguchi A; Nagao S; Itoh K; Miura S
Oncol Rep; 2002; 9(6):1307-12. PubMed ID: 12375039
[TBL] [Abstract][Full Text] [Related]
17. Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival.
Sorrentino C; Yin Z; Ciummo S; Lanuti P; Lu LF; Marchisio M; Bellone M; Di Carlo E
J Immunother Cancer; 2019 Jul; 7(1):201. PubMed ID: 31366386
[TBL] [Abstract][Full Text] [Related]
18. A Mutation in the Carbohydrate Recognition Domain Drives a Phenotypic Switch in the Role of Galectin-7 in Prostate Cancer.
Labrie M; Vladoiu M; Leclerc BG; Grosset AA; Gaboury L; Stagg J; St-Pierre Y
PLoS One; 2015; 10(7):e0131307. PubMed ID: 26168167
[TBL] [Abstract][Full Text] [Related]
19. Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth.
Rivera-Ramos A; Cruz-Hernández L; Talaverón R; Sánchez-Montero MT; García-Revilla J; Mulero-Acevedo M; Deierborg T; Venero JL; Sarmiento Soto M
Cancer Lett; 2024 Jun; 591():216879. PubMed ID: 38636895
[TBL] [Abstract][Full Text] [Related]
20. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression.
van den Brûle FA; Waltregny D; Liu FT; Castronovo V
Int J Cancer; 2000 Jul; 89(4):361-7. PubMed ID: 10956411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
